Skip to content

Low Risk Non ST Elevation Myocardial Infarction With or Without Intensive Care Unit Admission

Low Risk Non ST Elevation Myocardial Infarction With or Without Intensive Care Unit Admission : a Randomized Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05153889
Acronym
SELECTNSTEMI
Enrollment
320
Registered
2021-12-10
Start date
2021-12-18
Completion date
2025-07-31
Last updated
2024-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ST Elevated Myocardial Infarction

Keywords

Intensive Care Unit; General Cardiology Ward; ECG monitoring; Low risk NSTEMI

Brief summary

Favourable in-hospital outcome is observed in numerous patients after Non ST myocardial infarction (NSTEMI) with invasive strategy but European guidelines proposed systematic intensive care unit monitoring up to 24 h in lower risk patients (grade 1, level of evidence C). Regarding absence of prospective study supporting this strategy, we assessed the hypothesis that the lower risk NSTEMI patients identified through simple medical criteria and after coronary angiography evaluation may not require intensive care unit admission.

Detailed description

The incidence of serious in hospital complications after NSTEMI has dramatically decreased over the past decades mainly due to early coronary angioplasty with new generation drug eluting stents surrounded by an optimal antithrombotic treatment (1). Major in-hospital adverse events after NSTEMI became uncommon and above all appears predictable including unstable hemodynamic state, acute stent thrombosis and life threatening arrhythmia (5-7). Recent 2020 European guidelines recommended that all patients with NSTEMI should be monitored up to 24 hours or up to percutaneous coronary intervention (PCI) in the intensive care unit (ICU) and rhythm monitoring \> 24 h in patients at intermediate or high risk of cardiac arrhythmia (2). However, the usefulness of systematic ICU admission and ECG monitoring, for lower risk patients particularly when they have been stabilized with successful (PCI) has never been evaluated in a randomized study and remain controversial (8-10). The main objective of this randomized study is to validate the feasibility and safety of a strategy without intensive care unit admission of lower risk NSTEMI patients after coronary angiography evaluation and successful PCI when required, compared to the conventional strategy using systematic ICU monitoring. All patients admitted in our hospital for NSTEMI (initial admission of patients in ICU or directly in the cath lab) will have systematic coronary angiography evaluation and PCI when required. They will be classified as low or high risk patients related to guidelines derived criteria including results of coronary angiography evaluation. Low risk patients will be randomized in ICU admission group (control group) or general cardiology ward (GCW) group (experimental group) without ECG monitoring.

Interventions

OTHERHospitalized in Intensive care unit

Patient hospitalized in Intensive care unit with ECG monitoring

OTHERHospitalized in General cardiology ward

Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age \> or = to 18 years * NSTEMI was defined according guidelines with chest pain with or without ECG modifications and significant troponin elevation (hs-cTn T \*≥ 52 ng/l) or significant variation \> 10 ng/l between 2 dosages between 1 or 3 hours interval) \* Elecsys Roche * Coronary angiography mandatory \< 24 h after first troponin assay according to 2020 NSTEMI guidelines and PCI if required * Low risk NSTEMI defined with (all necessary): * Age\<85 years * Optimal antithrombotic therapy using new generation P2Y12 inhibitors (ticagrelor or prasugrel) or clopidogrel and aspirin with preloading at the latest before PCI * Success of PCI (one or 2 arteries) * Low risk of severe arrhythmia (ESC criteria) if none of the following criteria: haemodynamically unstable, major arrhythmias, LVEF \<40%, failed reperfusion, additional critical coronary stenosis of major vessels, complications related to percutaneous revascularization, * No major comorbidities requiring specific care * Success of PCI without any event within 30 minutes after the procedure * Low bleeding risk (ESC criteria) according to CRUSADE criteria validated in NSTEMI

Exclusion criteria

* STEMI * Unstable angina troponin \<5ng/l\* or \<14ng/l with variation \<4ng/l between 2 dosages )\* Elecsys Roche * High risk NSTEMI if one low risk criteria defined above is absent * Patient with acute coronary syndromes (ACS) requiring transfer to resuscitation unit and not to intensive care unit for any reason * Coronary angiography not performed or performed \> 24 h after first troponin assay in ICU * Pregnant or breastfeeding woman * Patient unable or refusing to sign inform consent * Patient without health care insurance * Patient under legal guardianship

Design outcomes

Primary

MeasureTime frameDescription
Success of the experimental strategy defined by absence of major adverse events 4 +/- 3 days after inclusion4 +/- 3 days after inclusionMajor adverse events include : mortality (total and cardiovascular), severe bleeding (BARC criteria \>2), major vascular events (BARC 3 or 4 criteria) , cardiac failure requiring specific therapy ,acute kidney injury (RAKIN classification ≥grade 2) , major neurologic events confirmed with brain imaging, severe conductive or rhythm disorder, new coronary ischemic event requiring coronary angiography, any medical decision for secondary ICU transfer

Secondary

MeasureTime frameDescription
Incidence of each event included in the combined primary outcome1 month follow upevaluation of each event of combined primary end point
Comparison of hospitalization length of stay for the 2 groupsthough hospital follow up, an average of 5 dayslenght of stay in ICU and total hospitalization stay in days
ICU length of stay in the control groupthough hospital follow up, an average of 5 daysICU length of stay in the control group in days
Evolution of patient satisfaction (questionnaire)1 month +/- 7 days after inclusiona short 5 questions by phone regarding satisfaction in the 2 groups
Incidence of low vs high risk NSTEMI patients admitted in ICU or in cath lab1 month follow upnumber of low vs high risk NSTEMI (flow chart)
Comparison of cardiovascular mortality in both arm1 month +/- 7 days after inclusioncardiovascular mortality in both arms
Comparison of new hospitalization for cardiac event in both arms1 month +/- 7 days after inclusionnew hospitalization for cardiac reasons
Comparison of direct medical cost of the initial inpatient stay in both armduring hospitalization stayeconomic study regarding medical cost
Comparison of total mortality in both arm1 month +/- 7 days after inclusiontotal mortality in both arms

Countries

France

Contacts

Primary ContactFlorence LECLERCQ, MD
f-leclercq@chu-montpellier.fr0467336188

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026